This invention provides a method for introducing substances into cells comprising contacting a composition comprising orally administered beta-glucan with said cells. This invention also provides a method for introducing substances into a subject comprising administering to the subject an effective
This invention provides a method for introducing substances into cells comprising contacting a composition comprising orally administered beta-glucan with said cells. This invention also provides a method for introducing substances into a subject comprising administering to the subject an effective amount of the above compositions. The substance which could be delivered orally includes but is not limited to peptides, proteins, RNAs, DNAs, chemotherapeutic agents, biologically active agents, plasmids, and other small molecules and compounds. Finally, this invention provides a composition comprising orally administered beta-glucan capable of enhancing efficacy of IgM and different uses of the said composition.
대표청구항▼
1. A method of treating cancer in a subject, comprising administering to said subject a soluble β-glucan in an amount effective to treat said cancer, wherein said glucan is derived from yeast and comprises a β-1,3 backbone with branches attached to the backbone via β-1,6 linkages, wherein the glucos
1. A method of treating cancer in a subject, comprising administering to said subject a soluble β-glucan in an amount effective to treat said cancer, wherein said glucan is derived from yeast and comprises a β-1,3 backbone with branches attached to the backbone via β-1,6 linkages, wherein the glucose units in said branches are β-1,3 linked, and said cancer is selected from the group consisting of neuroblastoma, melanoma, non-Hodgkin's lymphoma, breast cancer, non-small cell lung cancer, colorectal cancer, Epstein-Barr related lymphoma, Hodgkin's lymphoma, and epidermoid carcinoma. 2. The method of claim 1, wherein said glucan has a molecular weight of 10-350 kDa. 3. The method of claim 1, wherein said glucan is administered orally or intravenously. 4. The method of claim 1, wherein said glucan is administered at about 25 mg/kg/day. 5. The method of claim 1, further comprising administering a complement-activating antibody. 6. The method of claim 5, wherein said antibody is a monoclonal antibody. 7. The method of claim 5, wherein said antibody is administered simultaneously or sequentially with said glucan. 8. The method of claim 5, wherein said antibody is selected from the group consisting of cetuximab, M195, Dacluzimab, R24, Herceptin, Rituximab, 528, IgG, IgM, IgA, C225, Epratuzumab and 3F8. 9. The method of claim 5, wherein said antibody is cetuximab for treating non-small cell lung cancer. 10. The method of claim 5, wherein said antibody is cetuximab for treating colorectal cancer. 11. The method of claim 5, wherein said antibody is rituximab for treating non-Hodgkin's lymphoma. 12. The method of claim 1, further comprising administering a chemotherapeutic agent. 13. The method of claim 12, wherein said chemotherapeutic agent is carboplatin. 14. The method of claim 12, wherein said chemotherapeutic agent is irinotecan. 15. The method of claim 12, wherein said chemotherapeutic agent is paclitaxel. 16. The method of claim 12, wherein said glucan has a molecular weight of 10-350 kDa. 17. The method of claim 12, wherein said glucan is administered orally or intravenously. 18. The method of claim 12, wherein said glucan is administered at about 25 mg/kg/day. 19. The method of claim 12, wherein said chemotherapeutic agent is administered simultaneously or sequentially with said glucan. 20. The method of claim 12, wherein the cancer is non-small cell lung cancer.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (53)
Kozbor,Danuta; Kaneko,Yutaro, β-glucans encapsulated in liposomes.
Nikl Libor H. (Port Coquitlam CAX) Allbright Lawrence J. (Burnaby CAX), Composition and method to enhance the efficacy of a fish vaccine and to stimulate the immune system of fish.
Jamas Spiros ; Easson ; Jr. D. Davidson ; Ostroff Gary R., Enhancement of non-specific immune defenses by administration of underivatized, aqueous soluble glucans.
Bondeson Anders (Gothenburg SEX) Isaak Bernhard (Lausanne CHX) Perrenoud Andre (Nyon CHX) Tran Minh Q. (Lausanne CHX), High-performance gyrotron for production of electromagnetic millimeter or submillimeter waves.
Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is a.
Cheever, Martin A.; Disis, Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated.
Lane H. Clifford (Bethesda MD) Kovacs Joseph A. (Potomac MD) Fauci Anthony S. (Washington DC), Immunologic enhancement with intermittent interleukin-2 therapy.
Jamas Spiros (Boston MA) Easson ; Jr. D. Davidson (Shrewsbury MA) Ostroff Gary R. (Worcester MA), Method for immune system activation by administration of a b
상세보기
Jamas Spiros (Boston MA) Easson ; Jr. D. Davidson (Shrewsbury MA) Ostroff Gary R. (Worcester MA), Method for producing neutral glucans for pharmaceutical applications.
Williams David L. (River Ridge LA) Browder I. William (New Orleans LA) DiLuzio ; deceased Nicholas R. (late of Gretna LA by Nicholas M. DiLuzio ; legal representative), Methods and compositions for prophylactic and therapeutic treatment of infections.
Williams David L. (River Ridge LA) Browder I. William (New Orleans LA) Diluzio ; deceased Nicholas R. (late of Gretna LA by Nicholas M. Diluzio ; legal representative), Methods and compositions for prophylactic and therapeutic treatment of infections.
Brandt Michael (Iffeldorf DEX) Endl Josef (Weilheim DEX) Jungfer Herbert (Starnberg DEX) Albert Winfried (Eberfing DEX), Monoclonal antibodies against melanoma.
Schlessinger Joseph ; Givol David,ILX ; Bellot Francoise,FRX ; Kris Richard ; Ricca George A. ; Cheadle Christopher ; South Victoria J., Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same.
Chatterjee Malaya ; Foon Kenneth A. ; Chatterjee Sunil K., Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma.
Robbins Ernest A. (High Ridge MO) Seeley Robert D. (Crestwood MO), Process for the prevention and reduction of elevated blood cholesterol and triglycerides levels.
Williams David L. (River Ridge LA) Browder I. William (New Orleans LA) DiLuzio ; deceased Nicholas R. (late of New Orleans LA by Nicholas M. DiLuzio ; legal representative), Soluble phosphorylated glucan: methods and compositions for treatment of neoplastic diseases.
Donzis Byron A. (#18 W. Rivercrest Houston TX 77042), Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional u.
Donzis Byron A. (#18 W. Rivercrest Houston TX 77042), Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional u.
Anderson Darrell R. ; Hanna Nabil ; Leonard John E. ; Newman Roland A. ; Reff Mitchell E. ; Rastetter William H., Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen.
Jamas Spiros (Boston MA) Easson ; Jr. D. Davidson (Shrewsbury MA) Ostroff Gary R. (Worcester MA), Use of aqueous soluble glucan preparations to stimulate platelet production.
Jamas Spiros ; Easson ; Jr. D. Davidson ; Ostroff Gary R., Uses for underivatized, aqueous soluble .beta.(1-3) glucan and compositions comprising same.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.